JPRN-UMIN000019051已完成未知
Randomized, Placebo-controlled, Clinical Study to Investigate the Anti-Metabolic Syndrome Effect of the Functional Food in humans - Box Lunch Study at Kanagawa Prefecture
ot-for profit Organization Japan Clinical Research Support Unit0 个研究点目标入组 160 人开始时间: 2015年9月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Pregnancy, nursing or planning to become pregnant during the study (female only) 2) Any other significant medical conditions 3) Uncontrolled metabolic syndrome, or diabetes with insulin treatment 4) Severe allergies to wheat, soy, egg, milk, crustacean shellfish 5) Severe sensitivity to caffeine 6) Implantable electronic medical devices 7) Wearable electronic medical devices 8) Mechanical life support equipment 9) Metals as implantable materials 10) Dialysis patients 11) Participation in other clinical trials at enrollment 12) Any other considered by a study physician to be inappropriate for inclusion
研究者
相似试验
已完成
不适用
Randomized, Placebo-controlled, Clinical Study to Investigate the Anti-Metabolic Syndrome Effect of the Functional Food in humansObesityJPRN-UMIN000019041ot-for profit Organization Japan Clinical Research Support Unit160
尚未招募
4 期
Clinical Trial of Liveril Forte Tablet in subjects with Non-Alcoholic Fatty Liver Disease.CTRI/2022/10/046201Meyer Organics Pvt Ltd
尚未招募
4 期
Clinical Trial of Liveril Forte Tablet in subjects with Non-Alcoholic Fatty Liver Disease.CTRI/2022/10/046148Meyer Organics Pvt Ltd
尚未招募
4 期
Clinical Study to Evaluate the Efficacy and Safety in Healthy Adults for a period of 2 months for the safety endpoints.CTRI/2024/05/066815Herbal Creations
已完成
不适用
A randomized, blinded, placebo-controlled study to assess the safety, tolerability and pharmacokinetics of EGT710 following administration of single and multiple doses to healthy adults.COVID-19infectious disease caused by the SARS-CoV-2 virus (coronavirus)10047438NL-OMON53410ovartis Pharma AG100